Regulating HIF-2α stabilization with an intelligent switchable nanoplatform for tumor immunity reprogramming and...

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Cancer Therapy

Background:

• Chronic hypoxia is a major challenge in solid tumor treatment, particularly in hepatocellular carcinoma (HCC).
• Hypoxia promotes tumor progression, angiogenesis, immune suppression, and reduces therapeutic efficacy by upregulating hypoxia-inducible factor-2α (HIF-2α).
• Sonodynamic therapy (SDT) efficacy is limited by insufficient oxygen supply in hypoxic tumors.

Purpose of the Study:

• To develop an intelligent nanoplatform for overcoming chronic hypoxia and reprogramming the tumor microenvironment.
• To enhance the efficacy of sonodynamic therapy (SDT) and targeted therapies in hepatocellular carcinoma (HCC).
• To investigate the potential of nanoplatform-mediated immune reprogramming for solid tumor treatment.

Main Methods:

• Development of an organic-inorganic hybrid nanoplatform (VitK3/P-Ce6@H-MnO2) integrating oxygen self-supply and ROS generation.
• Utilizing the acidic tumor microenvironment as an endogenous switch to trigger H-MnO2 decomposition, releasing oxygen and Vitamin K3.
• Employing ultrasound as an exogenous switch to activate Ce6, inducing a reactive oxygen species (ROS) storm and immunogenic cell death (ICD).

Main Results:

• The nanoplatform effectively alleviated chronic hypoxia and facilitated HIF-2α degradation.
• Combined therapy with Lenvatinib suppressed abnormal angiogenesis and enhanced CD8+ T-cell infiltration.
• The nanoplatform reprogrammed the immunosuppressive tumor microenvironment, converting "cold tumors" to "hot tumors" and achieving synergistic therapeutic effects.

Conclusions:

• Nanoplatform-mediated immune microenvironment reprogramming is a controllable and effective strategy for solid tumors.
• The developed nanoplatform shows significant promise for hepatocellular carcinoma (HCC) treatment.
• This approach offers a potential breakthrough in overcoming therapeutic resistance driven by tumor hypoxia.